{
  "input": {
    "mode": "build_chain",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_acitretin",
          "name": "Acitretin"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_adalimumab",
          "name": "Adalimumab"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_etanercept",
          "name": "Etanercept"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_omalizumab",
          "name": "Omalizumab"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_secukinumab",
          "name": "Secukinumab"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_brodalumab",
          "name": "Brodalumab"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_apremilast",
          "name": "Apremilast"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_tildrakizumab",
          "name": "Tildrakizumab"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_guselkumab",
          "name": "Guselkumab"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "tegraph_snapshot": {
      "nodes": [],
      "edges": [],
      "round_index": 1
    },
    "constraints": {
      "require_disjoint_paths": 2,
      "max_new_nodes": 50,
      "max_new_edges": 64,
      "batched": true
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "graph_updates": {
      "add_nodes": [
        {
          "id": "drug_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_omalizumab",
          "type": "Drug",
          "label": "Omalizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tildrakizumab",
          "type": "Drug",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_guselkumab",
          "type": "Drug",
          "label": "Guselkumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_TNF",
          "type": "Target",
          "label": "TNF",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_IL17",
          "type": "Target",
          "label": "IL-17",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "pathway_inflammatory_response",
          "type": "Pathway",
          "label": "Inflammatory Response Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "disease_generalised_pustular_psoriasis",
          "type": "Disease",
          "label": "Generalised Pustular Psoriasis",
          "attrs": {
            "agent": "Proponent"
          }
        }
      ],
      "add_edges": [
        {
          "source": "drug_acitretin",
          "target": "target_TNF",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Acitretin的已知机制作用于TNF通路"
        },
        {
          "source": "drug_adalimumab",
          "target": "target_TNF",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "Adalimumab靶向TNF，适用于炎症性疾病"
        },
        {
          "source": "drug_etanercept",
          "target": "target_TNF",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "Etanercept作为TNF拮抗剂"
        },
        {
          "source": "drug_infliximab",
          "target": "target_TNF",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "Infliximab通过抑制TNF治疗多种皮肤病"
        },
        {
          "source": "drug_methotrexate",
          "target": "target_TNF",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Methotrexate可以降低TNF水平"
        },
        {
          "source": "drug_secukinumab",
          "target": "target_IL17",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Secukinumab特异性靶向IL-17"
        },
        {
          "source": "drug_ustekinumab",
          "target": "target_IL17",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Ustekinumab作用于IL-12和IL-23相关通路"
        },
        {
          "source": "drug_brodalumab",
          "target": "target_IL17",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Brodalumab通过抑制IL-17实现治疗"
        },
        {
          "source": "drug_apremilast",
          "target": "pathway_inflammatory_response",
          "relation": "modulates",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "Apremilast对炎症通路的调节作用"
        },
        {
          "source": "drug_tildrakizumab",
          "target": "target_IL17",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Tildrakizumab作为IL-23抑制剂"
        },
        {
          "source": "drug_guselkumab",
          "target": "target_IL17",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Guselkumab通过IL-23靶向作用"
        }
      ],
      "merge": [],
      "set_weights": []
    },
    "subconclusions": [
      {
        "id": "C1",
        "text": "多种药物通过不同作用靶点影响Generalised Pustular Psoriasis",
        "confidence": "high"
      }
    ],
    "assumptions": [
      "所有药物在目标组织中的有效浓度可达相关靶点"
    ],
    "uncertainties": [
      "各药物在长期使用中的安全性与有效性尚需进一步验证"
    ],
    "next_focus_for_pi": [
      "是否需要更多数据支持不同药物作用于该病的机制？"
    ]
  }
}